Bispecific antibody does not induce T-cell death mediated by chimeric antigen receptor against disialoganglioside GD2

Chimeric antigen receptors (CAR) and bispecific antibodies (BsAb) are two powerful immunotherapy approaches for retargeting lymphocytes toward cancer cells. Despite their success in lymphoblastic leukemia, solid tumors have been more recalcitrant. Identifying therapeutic barriers facing CAR-modified...

Descripción completa

Detalles Bibliográficos
Autores principales: Hoseini, Sayed Shahabuddin, Dobrenkov, Konstantin, Pankov, Dmitry, Xu, Xiaoliang L., Cheung, Nai-Kong V.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Taylor & Francis 2017
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5486173/
https://www.ncbi.nlm.nih.gov/pubmed/28680755
http://dx.doi.org/10.1080/2162402X.2017.1320625

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5486173/
https://www.ncbi.nlm.nih.gov/pubmed/28680755
http://dx.doi.org/10.1080/2162402X.2017.1320625

Ejemplares similares